IPO Week Preview

Key Takeaways

• All three Friday offerings are now reported priced: OPay at $19, Aspen at $15 and Bambusa at $16; actual opening trades remain unverified.
• Bambusa increased its offering to 10.55 million shares, raising $168.8 million gross, versus the earlier $150 million midpoint proposal.
• Aspen and OPay priced at their ranges’ low ends. Reported base gross proceeds are about $140.63 million and $304 million respectively.
• Gross proceeds exclude expenses. Pricing confirms transaction terms, not clinical success, future earnings or the direction of first-day trading.

With staff and AI research assistance By Frank Whitaker and Stan Rosenberg

Research cutoff 2026-10-30T15:58:00+00:00

Frank finds firmer numbers

The pencil marks have become prices. IPOScoop now reports OPay at $19, Aspen Neuroscience at $15 and Bambusa Therapeutics at $16. Friday October 30 remains their scheduled first-trade date in the calendar checked. I could verify the reported offering terms, but not the actual opening trades by this edition’s cutoff. [1][2][3][4]

Bambusa supplies the most consequential change in share supply. Its reported 10.55 million shares at $16 produce $168.8 million gross, up from roughly 9.375 million shares and $150 million at the original midpoint. The extra capital also means more shares sharing ownership. Neither figure should be confused with the cash left after underwriting and other expenses. [3]

Stan looks at what the capital must accomplish

Boston-based Bambusa develops antibodies that act on two biological targets for autoimmune and inflammatory diseases. Founder and chief executive Shanshan Xu leads the business. BBT001 addresses inflammation and itch in skin disease; BBT002 is being studied for respiratory and other inflammatory conditions. The company website describes the scientific aims, rather than establishing approved products or commercial success. [3][5]

IPOScoop reports no product revenue and a $48.7 million loss for the twelve months through June 30. That accounting loss is not a direct measure of cash consumed. Investors still need to examine clinical results, manufacturing, trial costs and subsequent funding requirements. Management’s planned Phase 2b BBT001 study start-up by year-end 2026 is a development window, not a guaranteed result. [3]

San Diego’s Aspen, founded in 2018 from research associated with Jeanne Loring, is developing sasineprocel, a patient-derived cell therapy intended to replace dopamine-producing neurons lost in Parkinson’s disease. Its reported $15 price is the low end of the former $15–$17 range. IPOScoop reports approximately $140.63 million gross proceeds and no product revenue, with a twelve-month loss of $66.84 million through June 30. [2]

Similar biotechnology labels do not make Aspen and Bambusa interchangeable. They pursue different mechanisms and diseases; trial outcomes and manufacturing demands will differ. Raising capital gives a programme resources to continue. It does not settle whether a treatment works. [2][3]

Frank separates price from prediction

OPay’s reported sixteen million depositary shares at $19 imply $304 million base gross proceeds. This is below the earlier $320 million midpoint illustration because the price changed, not because sixteen million shares became a different quantity. Each depositary share represents ten ordinary shares. Additional-share options and concurrent financing should be considered separately. [4]

OPay’s Singapore holding company operates financial services principally in Nigeria. Its payments and related services give readers an operating business to investigate, with currency, regulatory and competitive risks alongside growth. Its offering price is a transaction term, not a forecast for the market price. [4]

The calendar retains the week’s earlier SPACCircle and BHAV II reported pricings, Georgia Banking’s direct listing and BW Industrial’s unresolved former entry. A direct listing of existing shares does not itself raise new company capital. Those earlier entries are retained as previously sourced records, rather than newly verified trading outcomes.

Aspen’s anticipated Phase 3 dosing in the second half of 2027 and Bambusa’s year-end 2026 study start-up remain management windows. The Bambusa website checked at the cutoff did not establish another specifically dated future investor call or regulatory decision. Aspen’s announcement page could not be retrieved; its future event check remains incomplete. [2][3][5]

Analysis only; offering prices and past results do not predict returns.

Sources

[1] IPOScoop calendar — current reported pricing and scheduled trading dates. https://www.iposcoop.com/ipo-calendar/ [2] IPOScoop Aspen profile — terms, business, financials and development window. https://www.iposcoop.com/ipo/aspen-neuroscience/ [3] IPOScoop Bambusa profile — increased shares, price, finances and milestones. https://www.iposcoop.com/ipo/bambusa-therapeutics/ [4] IPOScoop OPay profile — pricing, depositary structure and business. https://www.iposcoop.com/ipo/opay/ [5] Bambusa company website — leadership, programmes and announcements. https://bambusatx.com/ Aspen announcement page was inaccessible during this run. Earlier-week calendar entries retain the October 29 edition’s source history; their trading outcomes were not independently reverified today.